Name: China Manufacturer Supply High Quality Benserazide Hydrochloride CAS 14919-77-8 with good service
Brand: Wuhan Fortuna Chemical Co., Ltd.

Specifications of Benserazide Hydrochloride CAS 14919-77-8

Items	Specifications	Results
Appearance	A white or yellowish-white or orange-white,crystalline powder	Yellowish-white crystalline powder
Solubility	Freely soluble in water,Very slightly soluble in anhydrous ethanol,Practically insoluble in acetone.	Complies
Identification	A:IR Should be identical to that of RS B:Chlorides Should be comply	Identical to that of RS Complies
Appearance of solution	Solution S is clear and not more intensely coloured than reference solution BY₆	Complies
PH	4.0 to 5.0	4.6
Related substances Impurity A Impurity B Impurity C Unspecified Impurity,each Sum of Impurities Other Than A	Not more than 0.5% Not more than 0.5% Not more than 0.5% Not more than 0.10% Not more than 1.0%	0.09% 0.23% UDL 0.03% 0.34%
Sulfated ash	Not more than 0.1%	0.05%
Heavy metals	Not more than 20ppm	＜20ppm
Water	Not more than 1.0%	0.61%
Assay (on the anhydrous basis）	Between 98.5% and 101.0%	100.2%
Residual solvents Methanol Ethanol	Not more than 3000ppm Not more than 5000ppm	1435ppm 174ppm
Conclusion	The product conforms to the above specifications.

Parameters of Benserazide Hydrochloride CAS 14919-77-8

Product parameters
Cas number:	14919-77-8
Appearance:	White or off-white crystalline powder
Purity:	98.5~101%
Package details:	1kg/foil bag; 25kg/drum
Brand:	Fortunachem

Benserazide hydrochloride is a synthetic drug used exclusively in combination with Levodopa (L-Dopa) for the treatment of Parkinson's disease. It is not effective on its own.

What It Is (Mechanism of Action):

Benserazide is a peripheral aromatic L-amino acid decarboxylase inhibitor (AAD inhibitor). In simple terms, it blocks an enzyme (decarboxylase) outside the brain, primarily in the digestive system and bloodstream.

Its Primary Use: Enabling Levodopa Therapy

Its sole, crucial use is to enhance the effectiveness of Levodopa, the primary medication for Parkinson's. Here’s how the combination works:

The Problem: Levodopa is the precursor to dopamine, which is deficient in the brains of Parkinson's patients. However, when taken alone, most Levodopa is converted into dopamine in the periphery (before it reaches the brain). This causes two major issues:

Reduced Efficacy: Less Levodopa crosses the blood-brain barrier.
Increased Side Effects: Peripheral dopamine causes nausea, vomiting, and heart rhythm disturbances.

The Solution (Benserazide's Role): Benserazide blocks the peripheral conversion of Levodopa to dopamine. This allows:

More Levodopa to reach the brain.
Lower doses of Levodopa to be effective.
Significantly fewer peripheral side effects (especially nausea).

Standard Medication:

Benserazide is always combined with Levodopa in a fixed-dose formulation. A common ratio is 1 part Benserazide to 4 parts Levodopa (e.g., 25 mg/100 mg). It is marketed under brand names such as Madopar® or Prolopa®.

Key Points:

Does not cross the blood-brain barrier: It only acts in the body's periphery, so it does not interfere with the desired conversion of Levodopa to dopamine in the brain.
Always combined: It is never prescribed as a standalone medication.
Core Parkinson's therapy: This combination (Levodopa + an AAD inhibitor like Benserazide or Carbidopa) remains the gold-standard, most effective symptomatic treatment for Parkinson's disease.

In summary, Benserazide hydrochloride is a critical "helper" drug that makes the primary Parkinson's medication (Levodopa) more effective and tolerable by preventing its breakdown in the body before it can reach the brain.